| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
18,090,000 |
| Market
Cap: |
1.31(B) |
| Last
Volume: |
562,071 |
Avg
Vol: |
560,510 |
| 52
Week Range: |
$49.57 - $89.2 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1017 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Ligand Pharmaceuticals is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Co. employs research technologies such as antibody discovery technologies, ion channel discovery technology, Pseudomonas fluorescens protein expression technology, formulation science and liver targeted pro-drug technologies to assist companies in their work toward securing prescription drug and biologic approvals. Co.'s collaboration partners and licensees have programs in clinical development targeting cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
4,000 |
6,500 |
| Total Buy Value |
$0 |
$0 |
$237,529 |
$444,439 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
1 |
2 |
| Total Shares Sold |
2,033 |
2,033 |
19,293 |
47,289 |
| Total Sell Value |
$153,034 |
$153,034 |
$1,480,968 |
$3,568,168 |
| Total People Sold |
2 |
2 |
3 |
5 |
| Total Sell Transactions |
2 |
2 |
5 |
12 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kozarich John W |
Director |
– • – |
2022-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,004 |
42,213 |
|
- |
|
| Aryeh Jason |
Director |
– • – |
2022-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,004 |
69,668 |
|
- |
|
| Cochran Jennifer R. |
Director |
– • – |
2022-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,004 |
2,165 |
|
- |
|
| Gray Nancy Ryan |
Director |
– • – |
2022-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,004 |
4,706 |
|
- |
|
| Davis Todd C |
Director |
– • – |
2022-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,004 |
51,786 |
|
- |
|
| Patel Sunil |
Director |
– • – |
2022-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,004 |
29,824 |
|
- |
|
| Boyce Sarah |
Director |
– • – |
2022-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,004 |
3,896 |
|
- |
|
| Lamattina John L |
Director |
– • – |
2022-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,004 |
26,402 |
|
- |
|
| Foehr Matthew W |
President and COO |
• – – |
2022-05-13 |
4 |
B |
$82.76 |
$206,910 |
D/D |
2,500 |
173,354 |
2.74 |
-6% |
|
| Higgins John L |
Chief Executive Officer |
• • – |
2022-05-09 |
4 |
OE |
$21.92 |
$175,360 |
D/D |
8,000 |
348,593 |
|
- |
|
| Kozarich John W |
Director |
– • – |
2022-02-28 |
4 |
S |
$102.62 |
$93,179 |
D/D |
(908) |
41,209 |
|
6% |
|
| Kozarich John W |
Director |
– • – |
2022-02-28 |
4 |
OE |
$12.53 |
$91,908 |
D/D |
7,335 |
42,117 |
|
- |
|
| Berkman Charles S |
SVP, Gen. Counsel & Secretary |
• – – |
2022-02-15 |
4 |
D |
$123.68 |
$195,167 |
D/D |
(1,578) |
30,394 |
|
- |
|
| Higgins John L |
Chief Executive Officer |
• • – |
2022-02-15 |
4 |
D |
$123.68 |
$732,557 |
D/D |
(5,923) |
340,593 |
|
- |
|
| Foehr Matthew W |
President and COO |
• – – |
2022-02-15 |
4 |
D |
$123.68 |
$438,569 |
D/D |
(3,546) |
170,854 |
|
- |
|
| Korenberg Matthew E |
EVP,Finance & Strategy and CFO |
• – – |
2022-02-15 |
4 |
D |
$123.68 |
$421,378 |
D/D |
(3,407) |
44,306 |
|
- |
|
| Foehr Matthew W |
President and COO |
• – – |
2022-01-26 |
4 |
D |
$113.68 |
$582,610 |
D/D |
(5,125) |
174,400 |
|
- |
|
| Foehr Matthew W |
President and COO |
• – – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
13,000 |
179,525 |
|
- |
|
| Korenberg Matthew E |
EVP,Finance & Strategy and CFO |
• – – |
2022-01-26 |
4 |
D |
$113.68 |
$412,431 |
D/D |
(3,628) |
47,713 |
|
- |
|
| Korenberg Matthew E |
EVP,Finance & Strategy and CFO |
• – – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
11,651 |
51,341 |
|
- |
|
| Higgins John L |
Chief Executive Officer |
• • – |
2022-01-26 |
4 |
D |
$113.68 |
$1,050,744 |
D/D |
(9,243) |
349,018 |
|
- |
|
| Higgins John L |
Chief Executive Officer |
• • – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
23,166 |
358,261 |
|
- |
|
| Berkman Charles S |
SVP, Gen. Counsel & Secretary |
• – – |
2022-01-26 |
4 |
D |
$113.68 |
$245,094 |
D/D |
(2,156) |
31,972 |
|
- |
|
| Berkman Charles S |
SVP, Gen. Counsel & Secretary |
• – – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
6,237 |
34,128 |
|
- |
|
| Lamattina John L |
Director |
– • – |
2021-11-16 |
4 |
S |
$161.86 |
$782,579 |
D/D |
(4,835) |
25,398 |
|
28% |
|
966 Records found
|
|
Page 4 of 39 |
|
|
0.90 (1.26%) 
